Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis.

Shinya Kajiura, Hironaga Satake, Ryuji Hayashi, Takayuki Yoshino

Abstract read

In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shinya KajiuraJSMO Secretariat Division, Japanese Society of Medical Oncology, Tokyo 105-0013, Japan.ORCID 0000-0003-4920-5130

Hironaga SatakeJSMO Secretariat Division, Japanese Society of Medical Oncology, Tokyo 105-0013, Japan.ORCID 0000-0001-7629-6803

Ryuji HayashiDepartment of Medical Oncology and Palliative Medicine, Toyama University Hospital, Toyama 930-0194, Japan.ORCID 0000-0002-4205-9540

Takayuki YoshinoPresident, Japanese Society of Medical Oncology, Tokyo 105-0013, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Japan's Center for Cancer Genomics and Advanced Therapeutics (C-CAT) provides a national platform for studying genomic-medicine-era care. We conducted a nationwide registry/database study to examine whether facility-level Japanese Society of Medical Oncology (JSMO) specialist availability was associated with first-line time to treatment failure (TTF) in lung cancer. The primary exposure was treating-facility JSMO specialist count (0-1 vs. ≥2); dual JSMO/Japanese Respiratory Society availability was a secondary lung-cancer-oriented exposure. First-line TTF was defined from systemic therapy start to recorded first-line treatment end or death, whichever occurred first. The cohort included 5456 patients at 241 facilities: 1477 in the 0-1 group and 3979 in the ≥2 group. Kaplan-Meier estimated median first-line TTF was 4.2 versus 5.1 months (log-rank

Indexed as

Lung NeoplasmsMedical OncologyAgedFemaleHumansJapanMaleMiddle AgedRegistriesTreatment Failurecancer-care infrastructureC-CATcomprehensive genomic profilinglung cancermedical oncologyreal-world datatime to treatment failuretreatment-process duration

Identifiers

PMID42645367

DOI10.3390/curroncol33080462

PMCPMC13511204

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.